The 9 months bearish chart indicates high risk for the $169.42M company. If the $1.26 price target is reached, the company will be worth $8.47 million less.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) saw a large growth in short interest in May. It has underperformed by 61.48% the S&P500. The stock of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) earned "Buy" rating by Mizuho on Wednesday, December 23. Therefore 67% are positive. Cryolife had 5 analyst reports since April 13, 2016 according to SRatingsIntel. Oppenheimer analysts stated on 27/10/2015 that they maintained their Outperform rating. The rating was upgraded by Ladenburg Thalmann on Friday, February 17 to "Buy". The firm earned "Buy" rating on Tuesday, August 11 by Brean Capital. BP plc (ADR) (NYSE:BP) has risen 15.51% since June 13, 2016 and is uptrending. It has outperformed by 43.95% the S&P500. Jfs Wealth Advsr Llc invested in 0% or 200 shares. Its down 0.17, from 1.07 in 2016Q3.
Sell-side analysts also have something to say about this company. BlackRock Fund Advisors raised its position in shares of Merrimack Pharmaceuticals by 10.5% in the third quarter. Sit Investment Associate Incorporated reported 26,950 shares or 0.04% of all its holdings.
Investors sentiment decreased to 0.9 in Q4 2016. Goldman Sachs Grp Inc has invested 0% in Cryolife Inc (NYSE:CRY). California State Teachers Retirement Sys holds 251,414 shares or 0% of its portfolio. State Of Alaska Department Of Revenue has invested 0.01% of its portfolio in Cryolife Inc (NYSE:CRY). Allianz Asset Mngmt Ag reported 0% stake. Oberweis Asset Inc reported 0.89% of its portfolio in Cryolife Inc (NYSE:CRY). The New York-based Citigroup Inc has invested 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). It also reduced Hutchison China Meditech Ltd stake by 165,881 shares and now owns 1.14M shares. Barclays Public Limited Liability Corp holds 0% or 58,915 shares. Ameriprise Financial stated it has 155,768 shares. Consonance Capital Management Lp owns 9.07 million shares or 4.06% of their USA portfolio. The insider Ali Wajid sold 477 shares worth $27,170.
Receive News & Ratings for Merrimack Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter. The company has market cap of $169.40 million. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. It now has negative earnings. The Firm has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. The Indus Capital Partners Llc holds 1.05 million shares with $4.28 million value, up from 500,000 last quarter. Therefore 40% are positive. Merrimack Pharmaceuticals has a one year low of $1.33 and a one year high of $6.79. The stock notched a 12-month high of $3.00 while $3.00 target is by far the most aggressive out of analysts who are now evaluating the company, $0 higher than the next highest 52-week price estimate. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Mgmt reported 0.01% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). JP Morgan downgraded the stock to "Neutral" rating in Friday, October 7 report. The firm has "Buy" rating by Dougherty & Company given on Friday, July 31. Oppenheimer has "Outperform" rating and $13 target. Cowen and Company reiterated a "market perform" rating on shares of Merrimack Pharmaceuticals in a research note on Friday, May 19th. Rhumbline Advisers reported 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK).
Since May 12, 2017, it had 0 insider buys, and 1 insider sale for $15,241 activity.
About 821,742 shares traded.